Key Takeaways Shares of KalVista Pharmaceuticals (KALV) have soared 36% in the past week, all thanks to the FDA's approval of its lead pipeline drug for the hereditary angioedema (HAE) indication. Earlier this week, the FDA approved the company's novel plasma kallikrein inhibitor, sebetralstat, for the treatment of acute (sudden) HAE attacks in individuals aged 12 years and older. The drug will be marketed under the brand name Ekterly. This latest approval makes Ekterly the first and only oral on-demand the ...